Aix Marseille Université, INSERM UMR-S1076, UFR de Pharmacie, Marseille, France.
Haematologica. 2012 Dec;97(12):1864-72. doi: 10.3324/haematol.2012.066167. Epub 2012 Jun 24.
We recently assigned a new fibrinolytic function to cell-derived microparticles in vitro. In this study we explored the relevance of this novel property of microparticles to the in vivo situation.
Circulating microparticles were isolated from the plasma of patients with thrombotic thrombocytopenic purpura or cardiovascular disease and from healthy subjects. Microparticles were also obtained from purified human blood cell subpopulations. The plasminogen activators on microparticles were identified by flow cytometry and enzyme-linked immunosorbent assays; their capacity to generate plasmin was quantified with a chromogenic assay and their fibrinolytic activity was determined by zymography.
Circulating microparticles isolated from patients generate a range of plasmin activity at their surface. This property was related to a variable content of urokinase-type plasminogen activator and/or tissue plasminogen activator. Using distinct microparticle subpopulations, we demonstrated that plasmin is generated on endothelial and leukocyte microparticles, but not on microparticles of platelet or erythrocyte origin. Leukocyte-derived microparticles bear urokinase-type plasminogen activator and its receptor whereas endothelial microparticles carry tissue plasminogen activator and tissue plasminogen activator/inhibitor complexes.
Endothelial and leukocyte microparticles, bearing respectively tissue plasminogen activator or urokinase-type plasminogen activator, support a part of the fibrinolytic activity in the circulation which is modulated in pathological settings. Awareness of this blood-borne fibrinolytic activity conveyed by microparticles provides a more comprehensive view of the role of microparticles in the hemostatic equilibrium.
我们最近在体外赋予了细胞衍生的微颗粒一种新的纤维蛋白溶解功能。在这项研究中,我们探讨了这种微颗粒的新特性与体内情况的相关性。
从血栓性血小板减少性紫癜或心血管疾病患者和健康受试者的血浆中分离循环微颗粒;还从纯化的人类血细胞亚群中获得微颗粒。通过流式细胞术和酶联免疫吸附试验鉴定微颗粒上的纤溶酶原激活物;通过比色法定量生成的纤溶酶,通过酶谱法测定其纤维蛋白溶解活性。
从患者中分离出的循环微颗粒在其表面产生一系列纤溶酶活性。这种特性与尿激酶型纤溶酶原激活物和/或组织型纤溶酶原激活物的含量有关。使用不同的微颗粒亚群,我们证明了内皮细胞和白细胞微颗粒上生成纤溶酶,但血小板或红细胞来源的微颗粒上则没有。白细胞衍生的微颗粒携带尿激酶型纤溶酶原激活物及其受体,而内皮细胞微颗粒携带组织型纤溶酶原激活物和组织型纤溶酶原激活物/抑制剂复合物。
携带组织型纤溶酶原激活物或尿激酶型纤溶酶原激活物的内皮细胞和白细胞微颗粒支持循环中部分纤维蛋白溶解活性,这种活性在病理状态下发生调节。对微颗粒所携带的这种血液来源的纤维蛋白溶解活性的认识,为微颗粒在止血平衡中的作用提供了更全面的视角。